Skip to main content
SpringerLink
Log in

Should everolimus be stopped after radiological progression in metastatic insulinoma? A “pro” point of view

  • Letter to the Editor
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. V. Tovazzi, V.D. Ferrari, A. Dalla Volta, F. Consoli, V. Amoroso, A. Berruti, Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view. Endocrine 69(3), 481–484 (2020)

    Article  CAS  Google Scholar 

  2. T. Brabander, W.A. van der Zwan, J.J.M. Teunissen, B.L.R. Kam, R.A. Feelders, W.W. de Herder, C.H.J. van Eijck, G.J.H. Franssen, E.P. Krenning, D.J. Kwekkeboom, Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 23(16), 4617–4624 (2017)

    Article  CAS  Google Scholar 

  3. W.T. Zandee, T. Brabander, A. Blazevic, B.L.R. Kam, J.J.M. Teunissen, R.A. Feelders, J. Hofland, W.W. de Herder, Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 104(4), 1336–1344 (2019)

    Article  Google Scholar 

  4. S. Satapathy, B.R. Mittal, 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Nucl. Med Commun. 40(12), 1195–1203 (2019)

    Article  CAS  Google Scholar 

  5. E. Medaer, C. Verslype, E. Van Cutsem, J. Dekervel, P.M. Clement, K. Nackaerts, A. Laenen, O. Gheysens, K. Goffin, S. Jentjens, K. Van Laere, C.M. Deroose, Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of (177)Lu-DOTATATE PRRT. Acta Oncol. 59(6), 644–651 (2020)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

    Wouter T. Zandee

  2. Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, the Netherlands

    Johannes Hofland & Wouter W. de Herder

Authors
  1. Wouter T. Zandee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Hofland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wouter W. de Herder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wouter W. de Herder.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zandee, W.T., Hofland, J. & de Herder, W.W. Should everolimus be stopped after radiological progression in metastatic insulinoma? A “pro” point of view. Endocrine 71, 256–257 (2021). https://doi.org/10.1007/s12020-020-02570-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-020-02570-4

Search

Navigation